Analgesic Allergies Linked to Pregnancy Risks
A study found that maternal nonnarcotic analgesic allergy labels (NNAALs) are associated with increased risks for eclampsia and preterm birth. Infants born to mothers with NNAALs also faced higher risks for neonatal opioid withdrawal syndrome and longer hospital stays. The findings suggest that proactive evaluations for patients with NNAALs could improve perinatal outcomes.
- ▪Maternal NNAALs were linked to a more than 60% higher risk for eclampsia and a nearly 20% higher risk for preterm birth.
- ▪Infants born to individuals with NNAALs had a nearly 50% higher risk for neonatal opioid withdrawal syndrome.
- ▪The study analyzed over 2.2 million singleton live births in California from 2016 to 2021.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/maternal-nonnarcotic-analgesic-allergy-labels-linked-2026a1000hfv?src=rss |
| Publication time | Wed, 27 May 2026 06:25:10 EDT |
| Retrieval time | 2026-05-27T10:37:58.859Z |
| Last seen | 2026-05-27T10:37:58.859Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | yFpRQwgeU_pA |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Maternal nonnarcotic analgesic allergy labels (NNAALs) were linked to a more than 60% higher risk for eclampsia and a nearly 20% higher risk for preterm birth. Infants born to individuals with NNAALs faced a nearly 50% higher risk for neonatal opioid withdrawal syndrome and longer hospital stays.METHODOLOGY:Researchers conducted a retrospective analysis using the Study of Outcomes in Mothers and Infants, a population-based cohort of all births in California between 2016 and 2021, with a total of 2,244,210 singleton live births with linked maternal-fetal records included in the analysis.Maternal NNAALs were identified using International Classification of Diseases, 10th Revision (ICD-10) code Z88.6 from hospital discharge, emergency department, and ambulatory surgery records for…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
